Engineering Guide · Vendor-Neutral

Sartorius Biostat STR vs Thermo HyPerforma vs Cytiva Xcellerex: Single-Use Bioreactor Comparison

Sartorius Biostat STR, Thermo HyPerforma S.U.B., and Cytiva Xcellerex XDR single-use bioreactor side-by-side comparison PG13.5 2x 3-BLADE SEGMENT TOP-DRIVEN MAGNETIC Biostat STR 50 - 2,000 L · Gen 3 Flexsafe STR bags BioPAT · XCell ATF option VS 2:1/5:1 PITCHED BLADE BOTTOM-MOUNTED HyPerforma S.U.B. 50 - 2,000 L · +DynaDrive 5,000 L BioProcess Container BPC Cube-shape DynaDrive scale VS Perf 4-PITCHED BLADE OFF-CENTRE BOTTOM Xcellerex XDR 10 - 2,000 L · X-platform Micro + macrosparger Perfusion door 1/2K L
Figure 1: The three market-leading single-use stirred-tank bioreactor platforms side-by-side. Sartorius Biostat STR (left) is a top-driven, magnetically coupled centre-line design with two 3-blade segment impellers and a ring sparger. Thermo HyPerforma S.U.B. (centre) is a bottom-mounted pitched-blade impeller with jacketed cylindrical geometry; the separate DynaDrive line extends the family to 3,000 L and 5,000 L cube-shaped vessels. Cytiva Xcellerex XDR (right) uses a four-pitched-blade, off-centred, bottom-mounted impeller with combined micro/macrosparger and an optional perfusion biocontainer loading door at 1,000 L and 2,000 L.
Quick Verdict

All three platforms deliver equivalent mixing time (below 30 s) and volumetric oxygen transfer (kLa above 10 h−¹) for standard CHO fed-batch mammalian cell culture from 50 L to 2,000 L, so raw hydrodynamics rarely decide the vendor. Choose Sartorius Biostat STR for the deepest CDMO installed base and integrated BioPAT + XCell ATF perfusion; choose Thermo HyPerforma when you need to scale past 2,000 L via the DynaDrive 5,000 L platform with 250 L minimum turndown; choose Cytiva Xcellerex XDR when you standardise on the Cytiva X-platform for continuous downstream and want an off-centred impeller with 5:1 turndown at commercial scale. Sartorius, Thermo, and Cytiva together hold just over 45% of 2024 SUB revenue.

Key differences at a glance

Side-by-side comparison

Factor Sartorius Biostat STR Thermo HyPerforma S.U.B. Cytiva Xcellerex XDR
Working volume range 50, 200, 500, 1,000, 2,000 L 50, 100, 250, 500, 1,000, 2,000 L (S.U.B.); +50, 500, 3,000, 5,000 L (DynaDrive) 10, 50, 200, 500, 1,000, 2,000 L
Impeller design 2× 3-blade segment, top-driven magnetically coupled Pitched-blade, bottom-mounted (S.U.B.); multi-impeller drive train (DynaDrive) 4-pitched-blade, off-centred, bottom-mounted
Vessel geometry Cylindrical jacketed stainless holder Cylindrical (S.U.B.); cube-shaped (DynaDrive) Cylindrical/rectangular jacketed holder
Bag family Flexsafe STR (multi-use DO/pH or optical DO/pH options) HyPerforma BioProcess Container (BPC) Xcellerex XDR biocontainer
Turndown ratio 4:1 typical (12.5 L minimum in 50 L) 2:1 or 5:1 (S.U.B.); 12–20:1 (DynaDrive at 3–5K L) 5:1 across full range
Published mixing time (2,000 L) <20 s at typical tip speed <30 s (5:1 S.U.B.); shorter at DynaDrive <30 s (extrapolated from XDR-10 characterisation)
Published kLa (mammalian, ring/macrosparger) >10 h−¹ standard, up to 40 h−¹ microsparger >10 h−¹ standard; >600 h−¹ in SUF microbial variant >10 h−¹ standard; up to 22.1 h−¹ at XDR-10 scale
Maximum single-vessel scale 2,000 L 5,000 L (DynaDrive) 2,000 L
Native cell-retention integration Integrated Repligen XCell ATF (Gen 3) External ATF/TFF via HyPerforma perfusion recirculation system Optional perfusion loading door (XDR-1000/2000)
Native automation platform Biobrain (successor to BioPAT MFCS) HyPerforma controller / DASGIP-derived software DeltaV or AVEVA (Allen-Bradley PLC on XDR-2000)
Estimated 2024 SUB market share (vendor) ~15% (single largest) ~15% combined (Thermo) ~15% combined (Cytiva/Danaher)

Values reflect the vendors' published Generation 3 (Sartorius), classic S.U.B. 5:1 and DynaDrive (Thermo), and X-platform-refreshed XDR (Cytiva, March 2025) datasheets. Your current-datasheet specifications take precedence. See the single-use bioreactor selection guide for the stirred-tank vs wave vs fixed-bed decision upstream of vendor choice.

Sartorius Biostat STR in detail

The Sartorius Biostat STR, currently in its Generation 3 platform, is the workhorse single-use stirred-tank bioreactor for mammalian cell culture across process development, clinical manufacturing, and commercial biologics production. The family spans five vessel sizes — 50, 200, 500, 1,000, and 2,000 L working volume — and pairs with the Flexsafe STR bag family under a design paradigm Sartorius calls "one-for-all scale-up," where the same conical impeller geometry, sparger topology, and H/D ratio scale unchanged from 50 L bench to 2,000 L production.

How it works

The Biostat STR uses two 3-blade segmented impellers on a magnetically coupled centre-line shaft, top-driven by an AC motor sitting on the vessel head plate. The Flexsafe STR bag installs into a jacketed stainless-steel holder that provides thermal control (typical 4–40 °C for mammalian culture), load-cell weight measurement, and mechanical support during agitation. Gas delivery is via a choice of ring sparger (typical for macro-oxygenation with air/oxygen at 0.02–0.1 vvm) or micro sparger (used when the process pushes into higher kLa territory at high cell density). Published engineering characterisation by De Wilde et al. (2014, BioProcess International) reports mixing times of 2–20 s across the 2 L to 2,000 L scale range and kLa values greater than 10 h−¹ readily achievable at all scales, with up to 40 h−¹ at 2,000 L in microsparger operation. Sartorius Generation 3 adds factory-integrated Repligen XCell ATF hollow-fibre cell retention as a supported option for intensified fed-batch and perfusion, plus the Biobrain automation platform that replaces the legacy BioPAT MFCS control tower.

When Biostat STR wins

Sartorius wins on installed CDMO base and tech-transfer predictability. Biostat STR is the reference platform at Samsung Biologics (~784,000 L of commercial capacity across five plants in Songdo), WuXi Biologics, Boehringer Ingelheim BioXcellence, and much of the Sartorius-adjacent European CDMO fleet, so a process transferred from a Biostat STR PD line lands on an identical geometry at commercial scale. If your programme is CDMO-manufactured for clinical or commercial supply, the transfer risk is lowest here. The Generation 3 XCell ATF integration also makes it the smoothest platform for teams whose fed-batch strategy specifically needs perfusion-based N-1 seed generation.

Thermo HyPerforma S.U.B. and DynaDrive in detail

Thermo Fisher's single-use bioreactor portfolio spans two related product families. The HyPerforma S.U.B. is the classic cylindrical stirred-tank single-use bioreactor, available at 50, 100, 250, 500, 1,000, and 2,000 L in both 5:1 and 2:1 turndown geometries. The HyPerforma DynaDrive is the next-generation platform introduced to overcome mixing and mass-transfer ceilings at commercial scale — it uses a cube-shaped vessel and a novel multi-impeller drive train, and extends the range to 3,000 L and 5,000 L, the largest single-use bioreactor commercially available. Both families use HyPerforma BioProcess Container (BPC) bags with reusable BioProcess Controllers.

How it works

The classic HyPerforma S.U.B. uses a pitched-blade impeller on a bottom-mounted magnetically coupled shaft, driven by an AC motor and jacketed for thermal control. Two turndown geometries are offered per size: the 5:1 model has a taller aspect ratio (H/D ~2) for higher kLa at commercial scale and is preferred for microbial or high-cell-density mammalian; the 2:1 model has a wider H/D ~1 for gentle mixing and lower shear, preferred for shear-sensitive cell lines. The HyPerforma 5:1 S.U.B. brochure quantifies performance at each scale. The DynaDrive S.U.B. departs from the cylindrical stirred-tank archetype entirely: a cube-shaped vessel houses multiple impellers on a drive train that delivers higher power input per unit volume (P/V) than a classic S.U.B. at the same tip speed, achieving shorter mixing times, higher kLa, and lower minimum working volume. Thermo publishes a 250 L minimum working volume in the 3,000 L and 5,000 L DynaDrive vessels — a turndown of 12–20:1 — which lets a single seed train span two more generations without an intermediate vessel handoff. Thermo's own economics claim a 25% production-cost reduction versus a matched classic S.U.B. seed train through fewer reactors, less consumables, and less labour.

When HyPerforma wins

Thermo wins whenever the programme's mass-balance demands push past what a 2,000 L single-use bioreactor can deliver. DynaDrive 3,000 L and 5,000 L are the only commercially available single-use bioreactors above 2,000 L; if you want single-use disposables at that scale (for facility flexibility, faster changeover, or lower cleaning validation burden) HyPerforma is currently the only option. DynaDrive is also the strongest choice for consolidating a long seed train — the 12–20:1 turndown lets one vessel serve two seed generations, which reduces the number of reactors on the plant floor. On the classic S.U.B. side, Thermo wins in fill-finish-adjacent bioprocess facilities that already run the Thermo Fisher (formerly Life Technologies, Millipore) stack, and in fermentation applications via the HyPerforma SUF (Single-Use Fermentor) variant that achieves kLa greater than 600 h−¹ for microbial culture. The February 2025 Thermo Fisher acquisition of Solventum's Purification and Filtration business further strengthens Thermo's single-use portfolio.

Cytiva Xcellerex XDR in detail

The Cytiva Xcellerex XDR single-use stirred-tank family originated with Xcellerex Inc., was acquired by GE Healthcare, and is now marketed by Cytiva (part of Danaher). The XDR line spans XDR-10, XDR-50, XDR-200, XDR-500, XDR-1,000, and XDR-2,000 for cell culture applications with a consistent 5:1 turndown across the range. In March 2025 Cytiva expanded the "X-platform" branding to formally include the refreshed XDR-500 and XDR-2000 with tighter integration to the Cytiva ReadyToProcess X-station continuous downstream infrastructure — the Xcellerex XDR is now the upstream anchor for Cytiva's end-to-end continuous manufacturing story.

How it works

The Xcellerex XDR uses a distinctive off-centred, bottom-mounted impeller with four pitched blades on a magnetically coupled shaft driven from below. The off-centre placement provides asymmetric flow that avoids the central vortex of a conventional centre-line stirred tank and improves gas dispersion at low agitation rates. Sparging is via two families of interchangeable elements: microsparger with 2 μm or 20 μm nominal pore size for high-kLa oxygen delivery, and drilled-hole macrosparger with 0.5 mm or 1.0 mm holes for CO₂ stripping and low-shear operation. Sensor integration is via standard 12 mm and 25 mm PG13.5 ports that accept Hamilton VisiFerm and PreSens optical DO/pH, biocapacitance probes, and Raman spectroscopy flow cells. Published engineering characterisation by Kreitmayer et al. (2022, Bioengineering) for the XDR-10 reports mixing times below 30 s across all tested conditions and kLa up to 22.1 h−¹, confirming "hydrodynamic conditions well suited for the cultivation of animal cells despite the unusual design of a single bottom-mounted impeller and an unbaffled cultivation bioreactor." An optional perfusion-specific biocontainer loading door is available for the 1,000 L and 2,000 L systems to accommodate external ATF or TFF cell retention devices, and the 1,000 L and 2,000 L systems ship with a semi-automatic hoist that simplifies biocontainer installation. Control uses Cytiva's DeltaV configuration or an Allen-Bradley PLC/PAC with AVEVA HMI on the XDR-2000.

When Xcellerex wins

Cytiva wins when the downstream train is Cytiva. Xcellerex XDR pairs natively with the Cytiva ReadyToProcess single-use downstream stack (MabSelect PrismA Protein A capture, ReadyMate connectors, KTA ready single-use chromatography skids), so a facility that has standardised on Cytiva's end-to-end continuous manufacturing story gets the tightest hardware and software integration by staying inside the ecosystem. Xcellerex also wins on turndown — the 5:1 turndown is standard across the full range without a separate 2:1 SKU, so seed-train planning is simpler. The optional perfusion loading door on the XDR-1000 and XDR-2000 is a purpose-built engineering feature for high-density perfusion campaigns that other vendors bolt on externally.

Pros and cons

Sartorius Biostat STR

Advantages

  • Deepest CDMO installed base: Samsung Biologics, WuXi Biologics, Boehringer Ingelheim tech-transfer risk is lowest.
  • Factory-integrated Repligen XCell ATF for perfusion and intensified fed-batch in Generation 3.
  • Broadest single-vendor sensor and PAT ecosystem via Biobrain and BioPAT integration.
  • Well-documented scale-up: De Wilde et al. 2014 characterisation covers 2 L to 2,000 L unchanged.

Disadvantages

  • Ceiling at 2,000 L single-vessel; no roadmap to 5,000 L single-use.
  • Turndown of 4:1 is tighter than Cytiva's 5:1 and DynaDrive's 12–20:1.
  • Flexsafe STR bag lead times can stretch during industry-wide supply squeezes.
  • Biobrain automation platform migration from legacy MFCS DA is not always seamless for existing users.

Thermo HyPerforma S.U.B. and DynaDrive

Advantages

  • Only vendor with 3,000 L and 5,000 L single-use bioreactors on the market via DynaDrive.
  • Deepest turndown at scale: 12–20:1 on DynaDrive 3,000/5,000 L, enabling seed-train consolidation.
  • Two S.U.B. turndown geometries (5:1 tall for microbial/HCD and 2:1 wide for shear-sensitive) with matched BPC bags.
  • Strong microbial fermentation variant (SUF) with kLa greater than 600 h−¹.

Disadvantages

  • Two families to learn: classic S.U.B. and DynaDrive have different geometries and control paradigms.
  • Weaker CDMO tech-transfer story than Sartorius outside the Thermo-adjacent fleet.
  • Native cell retention is external (via HyPerforma perfusion recirculation) rather than factory-integrated.
  • Automation stack has fragmented origins (DASGIP-derived + Thermo controller) and requires per-site standardisation.

Cytiva Xcellerex XDR

Advantages

  • Tightest integration with Cytiva ReadyToProcess single-use downstream for end-to-end continuous manufacturing.
  • Consistent 5:1 turndown across the full XDR-10 to XDR-2000 range simplifies seed-train planning.
  • Purpose-built perfusion biocontainer loading door on XDR-1000 and XDR-2000.
  • Off-centre impeller design provides asymmetric flow and effective gas dispersion at low agitation.

Disadvantages

  • Ceiling at 2,000 L single-vessel; no path to 5,000 L single-use.
  • Smaller CDMO installed base than Sartorius; tech transfer often requires geometry-adaptation.
  • Off-centred, unbaffled design is less familiar to engineers trained on Rushton/Sartorius centre-line geometry.
  • Automation stack (DeltaV or AVEVA + Allen-Bradley) can be heavy for small biotech users who do not need process-control-system depth.

Which vendor should you choose?

Pick based on the dominant constraint: CDMO tech-transfer risk, scale ceiling, downstream integration, or perfusion architecture.

CDMO manufacturing at Samsung, WuXi, or BI

Tech transfer risk dominates the decision. Biostat STR is the reference geometry at the largest mAb CDMO fleet, so identical PD-to-commercial scale-up minimises characterisation work.

Choose Sartorius Biostat STR

Need to scale past 2,000 L single-use

High-titer mAb or vaccine programme requiring 3,000–5,000 L single-use to defer stainless-steel capex, or a seed train that benefits from 12–20:1 turndown to consolidate generations.

Choose Thermo HyPerforma DynaDrive

End-to-end continuous / X-platform downstream

Facility standardised on Cytiva ReadyToProcess Protein A capture, KTA single-use chromatography, and integrated continuous downstream. Xcellerex XDR is the native upstream anchor.

Choose Cytiva Xcellerex XDR

Perfusion or intensified fed-batch

Programme needs factory-integrated XCell ATF cell retention for perfusion or N-1 seed intensification. Biostat STR Generation 3 offers the tightest ATF hardware/software integration.

Choose Sartorius Biostat STR (Gen 3)

Real-world use cases

How process teams typically converge on one vendor for a specific problem.

CHO mAb clinical · 500–2,000 L
Sartorius Biostat STR at a Tier-1 CDMO

A clinical mAb programme entering Phase 2/3 with a CDMO manufacturing plan at Samsung Biologics or WuXi Biologics. Biostat STR is already qualified at the CDMO site, so the PD lab installs the matching 50 L or 200 L Biostat STR to eliminate geometry-adaptation work.

High-volume mAb · 3,000–5,000 L
Thermo HyPerforma DynaDrive for facility flex

A high-titer commercial mAb needs 5,000–10,000 kg/year but the facility strategy is single-use for changeover flexibility and lower cleaning-validation burden. Two DynaDrive 5,000 L vessels replace the classic 4× 2,000 L stainless-steel approach.

Continuous biomanufacturing · 500 L
Cytiva Xcellerex XDR into ReadyToProcess

A perfusion mAb programme pairs an XDR-500 with the perfusion biocontainer door and TFF cell retention, feeding directly into a Cytiva ReadyToProcess Protein A capture skid and continuous downstream train. Single-vendor integration reduces validation scope.

Vaccine or gene therapy · 200 L
Any vendor — qualified sensor stack matters more

For a vaccine or AAV programme at 200 L working volume, all three platforms deliver equivalent hydrodynamics. The decision usually comes down to which vendor's sensor stack (optical DO/pH, biocapacitance, Raman) is already qualified in the process quality system.

Not sure which sensor stack fits your Biostat STR, HyPerforma, or Xcellerex line?

The Bioreactor Sensor Selection Tool asks 6 questions about your scale, modality, and PAT ambition and returns a ranked shortlist of optical DO, pH, biocapacitance, and Raman probes qualified across all three single-use bioreactor platforms.

Open the Sensor Selection Tool

Cost and lifecycle considerations

3-year total cost of ownership is dominated by consumables and labour, not capital

Capital cost for a fully instrumented 2,000 L single-use bioreactor system is USD 0.6–1.2 million per line, but over a 3-year window with 30 batches per year the bag consumables (USD 4,000–8,000 per batch), reusable-sensor calibrations, and labour dominate at roughly 65–75% of TCO. Optimising the wrong cost lever wastes engineering effort.

All three vendors price their 2,000 L systems in the USD 0.6–1.2 million range for a fully instrumented line (vessel holder, control tower, DO/pH/temperature/pressure sensors, master station). Sartorius and Cytiva typically land at the higher end when bundled with their proprietary sensor and automation ecosystems (BioPAT, DeltaV); Thermo's classic HyPerforma S.U.B. is often the lowest-capex option, though DynaDrive at 5,000 L is a separate capital tier.

Bag consumables are the recurring cost. A 2,000 L Flexsafe STR, HyPerforma BioProcess Container, or Xcellerex biocontainer runs USD 4,000–8,000 per batch depending on sensor and impeller configuration. At 30 batches per year over 3 years that is USD 360,000–720,000 in bag spend alone per line. Reusable optical DO/pH sensors (Hamilton VisiFerm, PreSens) amortise across ~50–100 batches; single-use sensor patches for optical DO/pH add roughly USD 100–300 per batch.

Labour and QC cost tracks batch count and staffing model. Assume USD 500,000–1,000,000 over 3 years per 2,000 L line for shift operators, QA release testing, and environmental monitoring. For a full 3-year, 30-batch/year 2,000 L line the total cost of ownership sits at roughly USD 2.0–3.7 million. The crossover point where stainless-steel becomes cheaper is 2,000–5,000 L working volume with 30+ batches per year — see the dedicated single-use vs stainless-steel cost comparison and the Fermentation Economics Calculator for the model.

Cost component (3 yrs, 30 batches/yr, 2,000 L) Sartorius Biostat STR Thermo HyPerforma S.U.B. Cytiva Xcellerex XDR
Capital (vessel + control tower + sensors)USD 0.8–1.2MUSD 0.6–1.0MUSD 0.8–1.2M
Bag consumables (USD 4k–8k × 90)USD 0.36–0.72M (Flexsafe STR)USD 0.36–0.72M (BPC)USD 0.36–0.72M (Xcellerex)
Sensor amortisation + patchesUSD 0.1–0.3MUSD 0.1–0.3MUSD 0.1–0.3M
Labour + QA releaseUSD 0.5–1.0MUSD 0.5–1.0MUSD 0.5–1.0M
3-year TCO estimateUSD 1.8–3.2MUSD 1.6–3.0MUSD 1.8–3.2M

Vendor landscape

Beyond the big three, the single-use stirred-tank market includes several credible alternative and complementary vendors. Sartorius, Thermo Fisher, and Cytiva together hold just over 45% of 2024 revenue; the remainder is fragmented.

Sartorius platform

Thermo Fisher platform

Cytiva platform

Alternative vendors (the remaining ~55% of the market)

Frequently asked questions

What is the difference between Sartorius Biostat STR, Thermo HyPerforma S.U.B., and Cytiva Xcellerex XDR?
All three are cylindrical, stirred-tank single-use bioreactor platforms that scale from ~50 L to 2,000 L working volume for mammalian cell culture. The differences are architectural. The Sartorius Biostat STR uses two 3-blade segment impellers on a magnetically coupled top-driven centre-line shaft, sits in a jacketed stainless-steel holder, and pairs with Flexsafe STR bags — the same design scales from 50 L to 2,000 L unchanged. The Thermo HyPerforma S.U.B. uses a pitched-blade, bottom-mounted impeller with an AC motor drive and a jacketed cylindrical tank; its BioProcess Container bags come in both 5:1 and 2:1 turndown geometries, and a separate DynaDrive platform extends the family to 3,000 L and 5,000 L with a cube-shaped vessel and novel multi-impeller drive train. The Cytiva Xcellerex XDR uses a four-pitched-blade, off-centred bottom-mounted impeller with a rectangular jacketed holder, drilled-hole macrosparger and micro sparger options, and a semi-automatic bag hoist at 1,000–2,000 L; the XDR line spans XDR-10 through XDR-2000 with a 5:1 turndown.
What working volumes are available for each single-use bioreactor?
Sartorius Biostat STR Generation 3 covers 12.5 L (Biostat STR 50 minimum) to 2,000 L across five vessel sizes — 50, 200, 500, 1,000, and 2,000 L. Thermo HyPerforma S.U.B. is available at 50, 100, 250, 500, 1,000, and 2,000 L; the DynaDrive platform adds 50, 500, 3,000, and 5,000 L with lower turndown (250 L minimum working volume in the 3,000 L and 5,000 L vessels). Cytiva Xcellerex XDR spans XDR-10 (4.5–10 L), XDR-50, XDR-200, XDR-500, XDR-1,000, and XDR-2,000 for cell culture. All three families support scale-out from 50 L bench through 2,000 L clinical/commercial with consistent geometry rules for process transfer.
Which single-use bioreactor has the best mixing time and kLa performance?
Published engineering characterisation for all three families reports mixing times below 30 seconds and volumetric oxygen mass transfer coefficients (kLa) above 10 h−¹, which comfortably meets the 5–10 h−¹ required for typical CHO fed-batch mammalian cell culture. Sartorius reports Biostat STR mixing times of 2–20 s across 2 L to 2,000 L scales and kLa greater than 40 h−¹ at 2,000 L with microsparger operation. Cytiva's Xcellerex XDR-10 engineering characterisation (Kreitmayer et al. 2022, Bioengineering) reports mixing time below 30 s across all conditions and kLa up to 22.1 h−¹. Thermo's HyPerforma DynaDrive is designed for higher power input per unit volume than the classic 5:1 S.U.B. In practice all three deliver enough kLa headroom for standard mammalian titers; the differentiator is scale-up predictability, sensor integration, and CDMO capacity — not raw kLa.
What is the market share of Sartorius, Thermo Fisher, and Cytiva in single-use bioreactors?
The single-use bioreactor market was valued at approximately USD 4.58 billion in 2024 and is forecast to grow at a 14–17% CAGR through the early 2030s. Sartorius, Thermo Fisher Scientific, and Cytiva together hold just over 45% of 2024 revenue, with Sartorius the largest single vendor at roughly 15% market share. The remaining ~55% is split between Merck (Mobius), ABEC (Custom Single Run), Getinge/Applikon (AppliFlex STR), Eppendorf (BioBLU), PBS Biotech (PBS single-use), and long-tail rocking/wave players. Sartorius has the deepest CDMO and vaccine footprint (Biostat STR is the workhorse at Samsung Biologics, WuXi Biologics, and Boehringer Ingelheim); Thermo Fisher is expanding fast through the 2025 Solventum Purification and Filtration acquisition; Cytiva expanded its X-platform to 500 L and 2,000 L sizes in March 2025 and is winning share in continuous and perfusion applications.
How does HyPerforma DynaDrive compare to a classic single-use bioreactor?
The HyPerforma DynaDrive S.U.B. is Thermo Fisher's next-generation single-use platform designed to overcome the mixing and mass-transfer ceiling of classic cylindrical stirred tanks at scale. It uses a cube-shaped vessel with a multi-impeller drive train that delivers higher power input per unit volume (P/V) than a conventional 5:1 S.U.B. at the same tip speed, enabling higher cell densities and shorter mixing times. Working volumes reach 250 L in the 3,000 L and 5,000 L vessels — a turndown of 12–20:1 — which lets a single seed train span two more generations without a smaller-vessel handoff and cuts the number of reactors required for the seed train by up to 50%. Thermo publishes production-cost reduction of up to 25% through fewer reactors, less consumables, and less labour. DynaDrive complements rather than replaces the classic HyPerforma S.U.B. line, which remains the mainstream 50 L to 2,000 L platform.
Which single-use bioreactor is best for perfusion or intensified fed-batch?
All three vendors support perfusion and intensified fed-batch, but with different levels of built-in integration. The Sartorius Biostat STR Generation 3 is available with integrated Repligen XCell ATF hollow-fibre cell retention as a factory-supported option — the reactor, ATF module, sensors, and Biobrain automation are validated together. The Cytiva Xcellerex XDR-1000 and XDR-2000 offer an optional perfusion-specific biocontainer loading door that accommodates ATF or TFF cell retention devices; Cytiva also sells the ReadyToProcess X-station platform that pairs with XDR for continuous downstream. Thermo Fisher's HyPerforma S.U.B. supports both ATF and TFF externally and pairs with the HyPerforma perfusion recirculation system. For intensified fed-batch (N-1 perfusion seed feeding into a standard N-stage fed-batch), any of the three works — the choice depends on which cell retention device the user has qualified. See the dedicated ATF vs TFF for perfusion cell retention comparison for the retention-device decision itself.
What is the total cost of ownership for a 2,000 L single-use bioreactor?
Capital cost for a fully instrumented 2,000 L single-use bioreactor system (vessel holder, control tower, sensors, master station) sits at roughly USD 0.6–1.2 million per unit across all three vendors, with Sartorius and Cytiva typically at the higher end when bundled with their proprietary sensor and automation ecosystems. Bag consumables for a 2,000 L Flexsafe STR, BioProcess Container, or Xcellerex biocontainer land at USD 4,000–8,000 per batch depending on sensor and impeller configuration. Over a 3-year window with 30 batches per year, total cost of ownership is dominated by consumables — roughly USD 0.9–1.5 million on bags and reusable-sensor calibrations, plus USD 0.6–1.2 million capital, plus USD 0.5–1.0 million labour and QC — for a total of USD 2.0–3.7 million per 2,000 L line. The crossover point where stainless-steel becomes cheaper is 2,000–5,000 L and 30+ batches per year; see the single-use vs stainless-steel comparison for the crossover model.
Can I run all three single-use bioreactors with the same third-party PAT and sensors?
In principle yes — all three vendors accept standard optical DO and pH sensors (Hamilton VisiFerm, PreSens SFR, Mettler Toledo InPro 6970i, Pyroscience OXROB) via 12 mm and 25 mm PG13.5 ports, and all three support integrated Raman spectroscopy (Kaiser RXN2/RXN4, Endress+Hauser, Tornado Spectral Systems). Biocapacitance probes (Aber FUTURA, Hamilton Incyte) install through dedicated ports on all three families. In practice, however, each vendor tightly integrates their own sensor and automation stack: Sartorius BioPAT with the Biobrain control platform, Thermo's HyPerforma controller and DASGIP-derived software, and Cytiva's DeltaV or AVEVA-based bioreactor systems. Adding a third-party sensor is straightforward hardware-wise but often requires custom OPC UA integration, calibration procedures, and validation documentation. CDMOs typically standardise on the vendor's native ecosystem to avoid integration overhead across a fleet of reactors.

Resources and references